Northern Institute for Cancer Research, Newcastle upon Tyne NE2 4HH, United Kingdom.
J Biol Chem. 2010 Feb 26;285(9):6091-100. doi: 10.1074/jbc.M109.014092. Epub 2009 Dec 18.
The neuroectodermal tumors neuroblastoma and melanoma represent biologically aggressive and chemoresistant cancers. The chemotherapeutic agents fenretinide and bortezomib induce apoptosis through endoplasmic reticulum (ER) stress in these tumor types. The aim of this study was to test the hypothesis that the early events of ER stress signaling and response pathways induced by fenretinide and bortezomib are mediated by the eukaryotic initiation factor 2alpha (eIF2alpha)-ATF4 signaling pathway. Treatment of neuroblastoma and melanoma cell lines with fenretinide, bortezomib, or thapsigargin resulted in induction of eIF2alpha signaling, characterized by increased expression of phosphorylated eIF2alpha, ATF4, ATF3, and GADD34. These events correlated with induction of the pro-apoptotic protein Noxa. The cytotoxic response, characterized by up-regulation of Noxa and cell death, was dependent on ATF4, but not the ER-related pro-death signaling pathways involving GADD153 or IRE1. Although PERK-dependent phosphorylation of eIF2alpha enhanced ATF4 protein levels during ER stress, cell death in response to fenretinide, bortezomib, or thapsigargin was not abrogated by inhibition of eIF2alpha phosphorylation through PERK knockdown or overexpression of wild-type eIF2alpha. Furthermore, ATF4 induction in response to ER stress was dependent primarily on transcriptional activation, which occurred in a PERK- and phosphorylated eIF2alpha-independent manner. These results demonstrate that ATF4 mediates ER stress-induced cell death of neuroectodermal tumor cells in response to fenretinide or bortezomib. Understanding the complex regulation of cell death pathways in response to ER stress-inducing drugs has the potential to reveal novel therapeutic targets, thus allowing the development of improved treatment strategies to overcome chemoresistance.
神经外胚层肿瘤神经母细胞瘤和黑色素瘤代表了生物学上侵袭性和化疗耐药的癌症。芬维 A 酯和硼替佐米这两种化疗药物通过内质网 (ER) 应激诱导这些肿瘤类型发生细胞凋亡。本研究旨在检验以下假设:芬维 A 酯和硼替佐米诱导的 ER 应激信号转导和反应途径的早期事件是由真核起始因子 2alpha (eIF2alpha)-ATF4 信号通路介导的。用芬维 A 酯、硼替佐米或他普西龙处理神经母细胞瘤和黑色素瘤细胞系,导致 eIF2alpha 信号转导的诱导,其特征是磷酸化 eIF2alpha、ATF4、ATF3 和 GADD34 的表达增加。这些事件与促凋亡蛋白 Noxa 的诱导相关。以 Noxa 和细胞死亡上调为特征的细胞毒性反应依赖于 ATF4,但不依赖于涉及 GADD153 或 IRE1 的与 ER 相关的促死亡信号通路。虽然 PERK 依赖性 eIF2alpha 磷酸化增强了 ER 应激期间 ATF4 蛋白水平,但通过 PERK 敲低或野生型 eIF2alpha 的过表达抑制 eIF2alpha 磷酸化,并不会消除对芬维 A 酯、硼替佐米或他普西龙的细胞死亡反应。此外,对 ER 应激的 ATF4 诱导主要依赖于转录激活,这发生在 PERK 和磷酸化 eIF2alpha 独立的方式下。这些结果表明,ATF4 介导了神经外胚层肿瘤细胞对芬维 A 酯或硼替佐米的 ER 应激诱导的细胞死亡。了解对 ER 应激诱导药物的细胞死亡途径的复杂调控,有可能揭示新的治疗靶点,从而开发出改进的治疗策略来克服化疗耐药性。